The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
Scientific presentation selector
Geo Regions
Important Notice Regarding the Scientific Information You Have Requested
You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.
Please acknowledge that you understand this before proceeding.
BackImportant Notice: The information provided here relates to investigational therapies. The safety and efficacy of these investigational therapies has not been proven.
Presentation
First-line (1L) Encorafenib + Cetuximab + mFOLFOX6 in East Asian Patients with BRAF V600E-mutant Metastatic Colorectal Cancer (mCRC): Results From The Phase 3 BREAKWATER Study
T. Yoshino, T.W. Kim, Y. Yuan, Z. Chen, J. Zhang, Y.-M. Yeh, K. Yamaguchi, Q. Wang, S. Kim, T. Masuishi, M. Shiozawa, C. Inagaki, A. Zhou, T. Usari, K. Olu, Y. Tian, X. Zhang, L. Shen
Poster
Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) ± mFOLFOX6 and chemotherapy (chemo) ± bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER)
Van Morris, Elena Elez, Jeanne Tie, Scott Kopetz, Eric Van Cutsem, Harpreet Wasan, Sara Lonardi, Cathy Eng, Takayuki Yoshino, Tae Won Kim, Lin Shen, Zhiyu Chen, Michael J. Raphael, Eduardo Polo Marques, Marieke Vollebergh, Tiziana Usari, Elena Beyzarov, Kelechi Olu, Xiaosong Zhang, Josep Tabernero
Poster
Subsequent therapies in the phase 3 BREAKWATER study of first-line encorafenib + cetuximab + mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer
Josep Tabernero, Eric Van Cutsem, Cathy Eng, Takayuki Yoshino, Harpreet Wasan, Fortunato Ciardiello, Timothy Maughan, Tae Won Kim, Rona Yaeger, Jayesh Desai, Elena Élez, Sara Lonardi, Lin Shen, Ying Yuan, Van Morris, Tiziana Usari, Katherine Liau, Kelechi Olu, Xiaosong Zhang, Scott Kopetz
Poster
First-line (1L) encorafenib + cetuximab + mFOLFOX6 in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) in China: results from the phase 3 BREAKWATER study
Xicheng Wang, Ying Yuan, Zhiyu Chen, Jun Zhang, Qi Wang, Xianling Liu, Yongqiang Li, Zuoxing Niu, Xiaoping Qian, Yan Li, Ting Xu, Yihui Zhu, Hui Zhang, Nan Li, Xiaosong Zhang, Lin Shen
Presentation
BREAKWATER: Analysis of first-line encorafenib + cetuximab + chemotherapy in BRAF V600E-mutant metastatic colorectal cancer
Scott Kopetz, MD, PhD, Takayuki Yoshino, MD, PhD, Eric Van Cutsem, MD, PhD, Cathy Eng, MD, FACP, FASCO, Tae Won Kim, MD, PhD, Harpreet Singh Wasan, MD, Jayesh Desai, FRACP, Fortunato Ciardiello, MD, PhD, Rona Yaeger, MD, Timothy S. Maughan, MD, Elena Beyzarov, PharmD, Xiaoxi Zhang, PhD, Graham Ferrier, PhD, Xiaosong Zhang, MD, PhD, Josep Tabernero, MD, PhD
Presentation
Encorafenib + Cetuximab (EC) + FOLFIRI for BRAF V600E-Mutant Metastatic Colorectal Cancer (mCRC): Updated Results From the BREAKWATER Safety Lead-In (SLI)
Josep Tabernero, Takayuki Yoshino, Tae Won Kim, Rona Yaeger, Jayesh Desai, Harpreet Wasan, Eric Van Cutsem, Fortunato Ciardiello, Tim Maughan, Cathy Eng, Jeanne Tie, Elena Elez, Sara Lonardi, Tiziana Usari, Erik Hahn, Samuel Dychter, Graham Ferrier, Xiaosong Zhang, Scott Kopetz